BR0015324A - Derivados de imidazopiridina como inibidores de fosfodiesterase vii - Google Patents

Derivados de imidazopiridina como inibidores de fosfodiesterase vii

Info

Publication number
BR0015324A
BR0015324A BR0015324-9A BR0015324A BR0015324A BR 0015324 A BR0015324 A BR 0015324A BR 0015324 A BR0015324 A BR 0015324A BR 0015324 A BR0015324 A BR 0015324A
Authority
BR
Brazil
Prior art keywords
indicates
carbon atoms
vii
imidazopyridine derivatives
phosphodiesterase inhibitors
Prior art date
Application number
BR0015324-9A
Other languages
English (en)
Inventor
Hans Michael Eggenweiler
Karl-August Ackermann
Rochus Jonas
Michael Wolf
Michael Gassen
Thomas Welge
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of BR0015324A publication Critical patent/BR0015324A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)

Abstract

Patente de Invenção: "DERIVADOS DE IMIDAZOPIRIDINA COMO INIBIDORES DE FOSFODIESTERASE VII". 1. Compostos de fórmula I em que R^ 1^ indica CONR^ 4^R^ 5^, R^ 2^ indica H ou A, R^ 4^ e R^ 5^, independentemente um do outro, indicam, cada um, H ou A^ 1^, R^ 3^ indica Hal, Hal indica F, CI, Br ou I, A indica alquila tendo 1 a 4 átomos de carbono A^ 1^ indica alquila tendo 1 a 10 átomos de carbono, X indica alquileno tendo 1 - 4 átomos de carbono, no qual um grupo etileno pode também ser substituído por uma dupla ou tripla ligação, e seus sais e/ou solvatos fisiologicamente aceitáveis, como inibidores de fosfodiesterase VII e seu uso para a preparação de um medicamento.
BR0015324-9A 1999-11-06 2000-10-25 Derivados de imidazopiridina como inibidores de fosfodiesterase vii BR0015324A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19953414A DE19953414A1 (de) 1999-11-06 1999-11-06 Imidazopyridinderivate als Phospodiesterase VII-Hemmer
PCT/EP2000/010525 WO2001034601A2 (de) 1999-11-06 2000-10-25 Imidazopyridinderivate als phosphodiesterase vii-hemmer

Publications (1)

Publication Number Publication Date
BR0015324A true BR0015324A (pt) 2002-07-09

Family

ID=7928107

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0015324-9A BR0015324A (pt) 1999-11-06 2000-10-25 Derivados de imidazopiridina como inibidores de fosfodiesterase vii

Country Status (22)

Country Link
US (1) US6613778B1 (pt)
EP (1) EP1226143B1 (pt)
JP (1) JP2003513973A (pt)
KR (1) KR20020044591A (pt)
CN (1) CN1387530A (pt)
AR (1) AR026352A1 (pt)
AT (1) ATE236157T1 (pt)
AU (1) AU775993B2 (pt)
BR (1) BR0015324A (pt)
CA (1) CA2388729A1 (pt)
CZ (1) CZ20021416A3 (pt)
DE (2) DE19953414A1 (pt)
DK (1) DK1226143T3 (pt)
ES (1) ES2192183T3 (pt)
HU (1) HUP0203245A3 (pt)
MX (1) MXPA02004448A (pt)
NO (1) NO20022124D0 (pt)
PL (1) PL355022A1 (pt)
PT (1) PT1226143E (pt)
SK (1) SK5732002A3 (pt)
WO (1) WO2001034601A2 (pt)
ZA (1) ZA200204510B (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1264843C (zh) * 2001-12-13 2006-07-19 第一阿斯比奥制药株式会社 具有pde7抑制作用的吡唑并嘧啶酮衍生物
DE10163991A1 (de) * 2001-12-24 2003-07-03 Merck Patent Gmbh Pyrrolo-pyrimidine
JP2006219374A (ja) 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Ｐｄｅ７阻害作用を有するイミダゾトリアジノン誘導体
JP2006219373A (ja) * 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Ｐｄｅ７阻害作用を有するピリジニルピラゾロピリミジノン誘導体
RU2376309C2 (ru) 2004-07-01 2009-12-20 Асубио Фарма Ко., Лтд. Производное тиенопиразола, имеющее ингибирующую фосфодиэстеразу 7 (pde 7) активность
CA2620333A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
EP2377530A3 (en) 2005-10-21 2012-06-20 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
WO2007053596A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
JP2009536669A (ja) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド アンジオテンシン調節による神経新生
EP2026813A2 (en) 2006-05-09 2009-02-25 Braincells, Inc. 5 ht receptor mediated neurogenesis
KR20090064418A (ko) 2006-09-08 2009-06-18 브레인셀즈 인코퍼레이션 4-아실아미노피리딘 유도체 포함 조합물
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
CA2681650C (en) * 2007-03-27 2016-11-22 Omeros Corporation The use of pde7 inhibitors for the treatment of movement disorders
US8637528B2 (en) 2007-03-27 2014-01-28 Omeros Corporation Use of PDE7 inhibitors for the treatment of movement disorders
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US9220715B2 (en) 2010-11-08 2015-12-29 Omeros Corporation Treatment of addiction and impulse-control disorders using PDE7 inhibitors
CN103547267A (zh) 2010-11-08 2014-01-29 奥默罗斯公司 使用pde7抑制剂治疗成瘾和冲动控制障碍
US20150119399A1 (en) 2012-01-10 2015-04-30 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
KR102640696B1 (ko) 2017-07-12 2024-02-27 다트 뉴로사이언스, 엘엘씨 Pde7 억제제로서 치환된 벤즈옥사졸 및 벤조푸란 화합물
WO2024038089A1 (en) 2022-08-18 2024-02-22 Mitodicure Gmbh Use of a therapeutic agent with phosphodiesterase-7 inhibitory activity for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intolerance

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3150486A1 (de) * 1981-12-19 1983-08-25 Merck Patent Gmbh, 6100 Darmstadt Imidazo(4,5-c)pyridine, diese enthaltende pharmazeutische zubereitungen und verfahren zu ihrer herstellung
US5120740A (en) 1989-11-03 1992-06-09 Wisconsin Alumni Research Foundation Prodrugs of 6-mercaptopurine and 6-thioguanine

Also Published As

Publication number Publication date
ATE236157T1 (de) 2003-04-15
DE19953414A1 (de) 2001-05-10
DE50001663D1 (de) 2003-05-08
PL355022A1 (en) 2004-03-22
AU775993B2 (en) 2004-08-19
US6613778B1 (en) 2003-09-02
AR026352A1 (es) 2003-02-05
EP1226143A2 (de) 2002-07-31
WO2001034601A3 (de) 2001-11-15
PT1226143E (pt) 2003-08-29
CA2388729A1 (en) 2001-05-17
ZA200204510B (en) 2003-11-26
HUP0203245A3 (en) 2003-12-29
DK1226143T3 (da) 2003-06-30
AU1387201A (en) 2001-06-06
EP1226143B1 (de) 2003-04-02
NO20022124L (no) 2002-05-03
ES2192183T3 (es) 2003-10-01
MXPA02004448A (es) 2004-09-10
CZ20021416A3 (cs) 2002-08-14
CN1387530A (zh) 2002-12-25
JP2003513973A (ja) 2003-04-15
WO2001034601A2 (de) 2001-05-17
KR20020044591A (ko) 2002-06-15
NO20022124D0 (no) 2002-05-03
HUP0203245A2 (hu) 2003-01-28
SK5732002A3 (en) 2002-09-10

Similar Documents

Publication Publication Date Title
BR0015324A (pt) Derivados de imidazopiridina como inibidores de fosfodiesterase vii
BR9916980A (pt) Derivados bicìclicos substituìdos úteis como agentes anticancerìgenos
BR0307267A (pt) Compostos heterocìclicos, ativos como inibidores de beta-lacta-mases
BR0014760A (pt) Derivados de purina
BR0011776A (pt) Derivados de purina
BR0111263A (pt) Derivados de 2-aminocarbonil-9h-purina
BR9807814A (pt) Composto, composição farmacêutica, uso de um composto, e, processos de tratamento e para preparação de um composto
BRPI0409986A (pt) derivados de pirimidina fundida com atividade de crf
BR0108408A (pt) Derivados de purina
BR0114089A (pt) Derivados de purina
BR9800524A (pt) Derivados de 1,3,8-triaza-espiro[4,5]decan-4-ona substituìda na posição 8
BR0109966A (pt) Combinação de compostos orgânicos
IT1311923B1 (it) Composti farmaceutici.
BR9906169A (pt) Derivados de pirrolo [1, 2-a] pirazina como ligandos sht 1a
BR0010072A (pt) 1-amino triazolo[4,3-a] quinazolina-5-onas e/ou -5-tionas inibidoras de fosfodiesterases iv
BR0213562A (pt) Benzimidazóis e análogos e seu uso como inibidores de cinases de proteìna
BR0317435A (pt) Derivados de pirimidina para o tratamento do crescimento celular anormal
BR0011705A (pt) Derivados de purina
BR9909253A (pt) Derivados de 2-ariletil-(piperidin-4-ilmetil) amina como antagonistas de receptor muscarìnico
BR9910144A (pt) Antagonistas de receptores de quimiocinas e seu uso
BRPI0408437A (pt) derivados de p-diaminobenzeno substituìdos, composição farmacêutica, e, uso da mesma
NO20040589L (no) Arylsulfonylderivater med 5-HT6 reseptor affinitet.
BR0015826A (pt) Derivados de benzotiadiazinas, seu processo de preparação e as composições farmacêuticas que os contêm
BR9714215A (pt) Derivados de benzoato de 1,4-diazabiciclo[2.2.2]oct-2-ilmetila, seu preparo e sua aplicação em terapêutica
BR9811582A (pt) Derivados de 4-oxo-3,5-di-hidro-4h-piridazino[4,5-b]indol-1-acetamid a, seu preparo e sua aplicação em terapêutica

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]